These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26175409)

  • 1. Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition.
    Stewart CA; Byers LA
    Cancer Cell; 2015 Jul; 28(1):4-6. PubMed ID: 26175409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
    Mohammad HP; Smitheman KN; Kamat CD; Soong D; Federowicz KE; Van Aller GS; Schneck JL; Carson JD; Liu Y; Butticello M; Bonnette WG; Gorman SA; Degenhardt Y; Bai Y; McCabe MT; Pappalardi MB; Kasparec J; Tian X; McNulty KC; Rouse M; McDevitt P; Ho T; Crouthamel M; Hart TK; Concha NO; McHugh CF; Miller WH; Dhanak D; Tummino PJ; Carpenter CL; Johnson NW; Hann CL; Kruger RG
    Cancer Cell; 2015 Jul; 28(1):57-69. PubMed ID: 26175415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
    Takagi S; Ishikawa Y; Mizutani A; Iwasaki S; Matsumoto S; Kamada Y; Nomura T; Nakamura K
    Cancer Res; 2017 Sep; 77(17):4652-4662. PubMed ID: 28667074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
    Fang Y; Liao G; Yu B
    J Hematol Oncol; 2019 Dec; 12(1):129. PubMed ID: 31801559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
    Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the development of histone lysine demethylase inhibitors.
    Maes T; Carceller E; Salas J; Ortega A; Buesa C
    Curr Opin Pharmacol; 2015 Aug; 23():52-60. PubMed ID: 26057211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations.
    Macheleidt IF; Dalvi PS; Lim SY; Meemboor S; Meder L; Käsgen O; Müller M; Kleemann K; Wang L; Nürnberg P; Rüsseler V; Schäfer SC; Mahabir E; Büttner R; Odenthal M
    Mol Oncol; 2018 Nov; 12(11):1965-1979. PubMed ID: 30220105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LSD1 Histone Demethylase Assays and Inhibition.
    Hayward D; Cole PA
    Methods Enzymol; 2016; 573():261-78. PubMed ID: 27372757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state.
    Yan W; Chung CY; Xie T; Ozeck M; Nichols TC; Frey J; Udyavar AR; Sharma S; Paul TA
    Mol Oncol; 2022 Mar; 16(6):1309-1328. PubMed ID: 34669238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties.
    Wang J; Lu F; Ren Q; Sun H; Xu Z; Lan R; Liu Y; Ward D; Quan J; Ye T; Zhang H
    Cancer Res; 2011 Dec; 71(23):7238-49. PubMed ID: 21975933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Design Concepts for LSD1-Selective Inhibitors.
    Ota Y; Suzuki T
    Chem Rec; 2018 Dec; 18(12):1782-1791. PubMed ID: 30277644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-
    Smitheman KN; Severson TM; Rajapurkar SR; McCabe MT; Karpinich N; Foley J; Pappalardi MB; Hughes A; Halsey W; Thomas E; Traini C; Federowicz KE; Laraio J; Mobegi F; Ferron-Brady G; Prinjha RK; Carpenter CL; Kruger RG; Wessels L; Mohammad HP
    Haematologica; 2019 Jun; 104(6):1156-1167. PubMed ID: 30514804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
    Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
    Hosseini A; Minucci S
    Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
    Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
    J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
    Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
    Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
    Mimasu S; Umezawa N; Sato S; Higuchi T; Umehara T; Yokoyama S
    Biochemistry; 2010 Aug; 49(30):6494-503. PubMed ID: 20568732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
    Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
    Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
    Naveen Sadhu M; Sivanandhan D; Gajendran C; Tantry S; Dewang P; Murugan K; Chickamunivenkatappa S; Zainuddin M; Nair S; Vaithilingam K; Rajagopal S
    Bioorg Med Chem Lett; 2021 Feb; 34():127763. PubMed ID: 33359604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
    Przespolewski A; Wang ES
    Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.